J&J/Merck fast-acting ibuprofen
This article was originally published in The Tan Sheet
Executive Summary
OTC joint venture expands worldwide product offerings with Dolormin, a lysenate ibuprofen compound developed by Merck and currently sold in Germany by Merck's Woelm Pharma OTC marketing arm. At an April 27 shareholderss meeting, Merck CEO Roy Vagelos called Germany "the first of many markets" for Dolormin.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning